Every 10-Q that MetaVia Inc. (MTVA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MTVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MTVA filings page.
MetaVia Inc., a clinical-stage biotech focused on cardiometabolic diseases, reported a net loss of $5.3 million for the quarter and $9.1 million for the six months ended June 30, 2026, driven by $9.4 million in combined research and development and general and administrative expenses.
Cash and cash equivalents were $12.6 million at June 30, 2026, up from $10.3 million at year-end, helped by a January 2026 underwritten equity offering, at-the-market sales, and warrant exercises that together provided $10.4 million of financing in the first half.
MetaVia highlights that its recurring losses, negative operating cash flows and limited cash raise substantial doubt about its ability to continue as a going concern within one year without additional capital. The company continues Phase 2a development of vanoglipel for MASH and Phase 1 trials of DA-1726 for obesity, with key data readouts planned in the fourth quarter of 2026.
MetaVia Inc. reported a net loss of $3.8M for the quarter ended March 31, 2026, similar to the prior-year loss of $3.7M. Operating expenses were $4.0M, with research and development at $2.1M and general and administrative at $1.9M. Cash and cash equivalents rose to $13.7M from $10.3M, helped by $7.1M in net proceeds from a January 2026 underwritten offering and about $0.3M from at-the-market share sales. The share count increased to 5,164,370 as of May 11, 2026, reflecting new equity and warrant exercises. The company highlights “substantial doubt” about its ability to continue as a going concern over the next year and plans to rely on additional equity, debt, warrant exercises, and potential partnerships. MetaVia continues to advance its cardiometabolic pipeline, including a Phase 2a MASH trial for vanoglipel and a multi-part Phase 1 obesity trial for DA-1726, with key DA-1726 dose-escalation data expected in the fourth quarter of 2026.
MetaVia Inc. (MTVA) reported Q3 2025 results showing a narrower net loss and lower spending while advancing its cardiometabolic pipeline. Net loss was $3.38 million on total operating expenses of $3.48 million, driven by a sharp reduction in R&D. Cash ended the quarter at $14.28 million with warrant liabilities of $0.17 million and stockholders’ equity of $6.33 million.
The company disclosed that conditions raise substantial doubt about its ability to continue as a going concern, despite stating existing cash should fund operations into 2026. MetaVia strengthened liquidity with a May 2025 private placement (net proceeds $9.1 million) and, on November 6, entered an at‑the‑market program of up to $2.3 million (3% commission) under its S‑3 shelf. Development highlights include positive Phase 2a top‑line for Vanoglipel (DA‑1241) and ongoing DA‑1726 Phase 1 multidose work, with 48 mg cohort top‑line expected in Q4 2025. As of November 5, 2025, common shares outstanding were 24,214,788.